Life Science Investing Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds
Life Science Investing Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds
Life Science Investing Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates
Life Science Investing Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During "J.P. Morgan Week 2026"
Life Science Investing Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates
Life Science Investing Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results
Life Science Investing Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance
Life Science Investing Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal
Life Science Investing Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials
Life Science Investing Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds
Life Science Investing Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds
Life Science Investing Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery
Life Science Investing Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission
SAGA Metals Completes Phase 2 of Major Drill Program at the Radar Project in Labrador-Confirms Extensive Oxide Mineralization in All Drill Locations at Trapper North and South Zones & Provides Corporate Update
